Bio-Rad Laboratories Inc. Class B

518.95-20.07-3.72%Vol 1281Y Perf -29.34%
Aug 9th, 2022 15:26 DELAYED
BID519.06 ASK521.64
Open518.95 Previous Close539.02
Pre-Market- After-Market-
 - -  - -%
Target Price
- 
Analyst Rating
— — 0.00
Potential %
- 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/-100 
Value Ranking
★★★+     54.35
Insiders Value % 3/6/12 mo.
-/-/-100 
Growth Ranking
★★+     50.18
Insiders Shares Cnt. % 3/6/12 mo.
-/-/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
15.26 
Earnings Rating
Buy
Market Cap15.41B 
Earnings Date
28th Jul 2022
Alpha0.01 Standard Deviation0.08
Beta0.79 

Today's Price Range

518.95518.95

52W Range

465.00818.60

5 Year PE Ratio Range

4.40275.30

Summary:

Neutral

Technical Indicators: Buy
Moving Averages: Sell
Performance
1 Week
-5.76%
1 Month
4.24%
3 Months
2.76%
6 Months
-17.28%
1 Year
-29.34%
3 Years
57.75%
5 Years
130.64%
10 Years
-

TickerPriceChg.Chg.%
BIO.B518.95-20.0700-3.72
AAPL164.920.05000.03
GOOG117.50-0.6400-0.54
MSFT282.301.98000.71
XOM90.591.64001.84
WFC43.400.21000.49
JNJ170.18-0.0200-0.01
FB196.640.99000.51
GE74.93-0.2500-0.33
JPM115.381.03000.90
 
ProfitabilityValueIndustryS&P 500US Markets
56.80
-7.80
-3.20
-3.40
-45.57
RevenueValueIndustryS&P 500US Markets
2.18B
430.42
8.24
6.41
Earnings HistoryEstimateReportedSurprise %
Q02 2022-3.38-
Q01 2022-4.94-
Q04 2021-3.21-
Q03 2021-3.71-
Q02 2021-3.54-
Q01 2021-5.21-
Q04 2020-4.01-
Q03 2020-3.00-
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume128
Shares Outstanding29.70K
Shares Float180.14K
Trades Count5
Dollar Volume66.43K
Avg. Volume551
Avg. Weekly Volume559
Avg. Monthly Volume711
Avg. Quarterly Volume384

Bio-Rad Laboratories Inc. Class B (NYSE: BIO.B) stock closed at 518.95 per share at the end of the most recent trading day (a -3.72% change compared to the prior day closing price) with a volume of 128.0000 shares and market capitalization of 15.41B. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 8000 people. Bio-Rad Laboratories Inc. Class B CEO is Norman Schwartz.

The one-year performance of Bio-Rad Laboratories Inc. Class B stock is -29.34%, while year-to-date (YTD) performance is -28.21%. BIO.B stock has a five-year performance of 130.64%. Its 52-week range is between 465 and 818.6, which gives BIO.B stock a 52-week price range ratio of 15.26%

Bio-Rad Laboratories Inc. Class B currently has a PE ratio of -110.90, a price-to-book (PB) ratio of 1.45, a price-to-sale (PS) ratio of 1.16, a price to cashflow ratio of 25.50, a PEG ratio of 2.32, a ROA of -0.73%, a ROC of -0.87% and a ROE of -1.00%. The company’s profit margin is -45.57%, its EBITDA margin is -3.20%, and its revenue ttm is $2.18 Billion , which makes it $430.42 revenue per share.

Of the last four earnings reports from Bio-Rad Laboratories Inc. Class B, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Bio-Rad Laboratories Inc. Class B’s next earnings report date is -.

The consensus rating of Wall Street analysts for Bio-Rad Laboratories Inc. Class B is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Bio-Rad Laboratories Inc. Class B stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Bio-Rad Laboratories Inc. Class B has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Bio-Rad Laboratories Inc. Class B has a Neutral technical analysis rating based on Technical Indicators (ADX : 83.46, ATR14 : 20.29, CCI20 : 7.22, Chaikin Money Flow : 0.58, MACD : -17.64, Money Flow Index : 41.48, ROC : 0.12, RSI : 49.75, STOCH (14,3) : 78.50, STOCH RSI : 0.90, UO : 46.16, Williams %R : -21.50), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Bio-Rad Laboratories Inc. Class B in the last 12-months were: Ajit Ramalingam (Option Excercise at a value of $0), Andrew J. Last (Option Excercise at a value of $598 480), Andrew J. Last (Sold 2 000 shares of value $1 626 203 ), Annette Tumolo (Option Excercise at a value of $1 799 043), Annette Tumolo (Sold 6 946 shares of value $5 233 746 ), Dara Wright (Option Excercise at a value of $0), Ilan Daskal (Option Excercise at a value of $283 122), Ilan Daskal (Sold 810 shares of value $668 537 ), Michael Crowley (Option Excercise at a value of $0), Norman Schwartz (Option Excercise at a value of $3 702 220), Timothy S. Ernst (Option Excercise at a value of $0)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating-
0.00
-
0.00
-
0.00

Bio-Rad Laboratories Inc. Class B

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (60% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the United States (40% of 2019 sales), Europe (33%), and Asia (22%), with Canada and Latin America accounting for the bulk of the remaining 5%. Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.

CEO: Norman Schwartz

Telephone: +1 510 724-7000

Address: 1000 Alfred Nobel Drive, Hercules 94547, CA, US

Number of employees: 8 000

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

67%33%

Bearish Bullish

60%40%

Bearish Bullish

69%31%


News

Stocktwits